Newsroom

Sorted by: Latest

-

Floor & Decor Announces New Store Opening in Florence, KY

ATLANTA--(BUSINESS WIRE)--Floor & Decor (NYSE: FND), the leading high-growth retailer specializing in hard-surface flooring for homeowners and professionals, today announced the opening of its newest warehouse store and design center in Florence, Kentucky, located at 87 Spiral Drive. The Florence store will open with a team of approximately 38 associates and is led by Gena Schobinger, the store's Chief Executive Merchant. Floor & Decor operates more than 280 warehouse-format stores and...
-

Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Radicle Science and Council for Responsible Nutrition (CRN) honored Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, as the winner of the 2026 Annette Dickinson Trailblazer Award. “This award is incredibly special to me because I had the...
-

Kopin to Introduce Expanded First‑Person Viewer Evaluation Kit Lineup at AUSA 2026

WESTBOROUGH, Mass.--(BUSINESS WIRE)--Kopin to Introduce Expanded First Person Viewer Evaluation Kit Lineup at AUSA 2026...
-

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE), for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC). VIR-5500 is being co-developed by Astellas Pharma Inc. and Vir Biotechnology through a global strategic collaboration. “Receiving Fast Track designation reflects the potent...
-

GATX Corporation Sets Date for 2026 Third-Quarter Earnings Release and Conference Call

CHICAGO--(BUSINESS WIRE)--GATX Corporation (NYSE: GATX) will report 2026 third-quarter results prior to market open on Oct. 29, 2026. GATX will hold a conference call later that morning to review the results. Investors can access the call by telephone or webcast as follows: Live Teleconference   Date:   Oct. 29, 2026   Time:   11 a.m. Eastern Time   Domestic Dial-In:   1 (833) 461-5787   International Dial-In:   1 (585) 542-9983   Access Code:   354 489 716   Live Webcast:   www.gatx.com To par...
-

BlackSky Wins Six-Figure Gen-3 On-Demand Pilot Contract with New International Intelligence Customer

HERNDON, Va.--(BUSINESS WIRE)--Blacksky wins six-figure Gen-3 On-Demand pilot contract with new international intelligence customer....
-

Empower AI Wins $205 Million DCSA Contract to Modernize Enterprise IT Support

RESTON, Va.--(BUSINESS WIRE)--Empower AI has been awarded the DCSA CSS contract, valued at $205 million, to deliver enterprise IT support across the agency's worldwide operations....
-

RB Global Announces Executive Leadership Appointments and Organizational Updates to Support Next Phase of Growth and Industry Leadership

WESTCHESTER, Ill.--(BUSINESS WIRE)--RB Global, Inc. (NYSE: RBA) (TSX: RBA) (“RB Global” or the “Company”) today announced executive leadership appointments and organizational updates to position the Company for its next phase of growth and industry leadership as the world’s most trusted global equipment marketplace. The leadership and organizational changes are effective today. “We have built RB Global into a powerful global marketplace with leading positions across increasingly diverse and att...
-

ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Global Chief Scientific and Medical Officer, will participate virtually in a fireside chat at the Piper Sandler Virtual Oncology Symposium, taking place October 15-16, 2026. Details of the event are provided below: Piper Sandler Virtual Oncology Symposium – Fireside Chat Participant: Patrick Soon-Shion...
-

Asahi Kasei Therapeutics Announces First Patient Dosed in Phase 2a Trial of AIC468 for BK Virus Infection in Kidney Transplant Recipients

TOKYO--(BUSINESS WIRE)--Asahi Kasei Therapeutics announced that the first patient has been dosed in a randomized Phase 2a clinical trial (NCT07503561) evaluating AIC468....